Desensitization to Filgrastim in a 2-Year-Old Girl With a Vaginal Endodermal Sinus Tumor

Filgrastim desensitization in a patient with Hodgkin lymphoma

“…[1][2][3][4][5][6] Hypersensitivity reactions to G-CSF formulations, such as filgrastim, pegfilgrastim, and biosimilars, are rare, and few reports exist regarding desensitization protocols, particularly in the pediatric population. [7][8][9] Below, we describe successful desensitization and subsequent use of G-CSF (biosimilar product: Nivestym) in an adolescent with a severe hypersensitivity reaction to pegfilgrastim. A 14-year-old previously healthy Caucasian female was diagnosed with classical Hodgkin lymphoma ( nodular sclerosing subtype, stage IIA with mediastinal bulky disease, intermediate risk) and received treatment per Children's Oncology Group study AHOD0031 (NCT00025259) with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide.…”